# Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

> **NCT06536049** · PHASE1,PHASE2 · RECRUITING · sponsor: **Yazeed Sawalha** · enrollment: 38 (estimated)

## Conditions studied

- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Grade 3b Follicular Lymphoma
- Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
- Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
- Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified
- Recurrent Primary Mediastinal Large B-Cell Lymphoma
- Recurrent Transformed Non-Hodgkin Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Grade 3b Follicular Lymphoma
- Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
- Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
- Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified
- Refractory Primary Mediastinal Large B-Cell Lymphoma
- Refractory Transformed Non-Hodgkin Lymphoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Computed Tomography
- **BIOLOGICAL:** Epcoritamab
- **DRUG:** Ibrutinib
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT06536049
- **Lead sponsor:** Yazeed Sawalha
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-02
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2026-02-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06536049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06536049, "Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06536049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*